Drug Information

Drug General Information
Drug ID
D01TVQ
Former ID
DAP000383
Drug Name
Ibritumomab
Synonyms
Zevalin (TN)
Drug Type
Antibody
Indication Non-hodgkin's lymphoma [ICD10:C85] Approved [536361]
Mantle cell lymphoma [ICD9: 200.4, 202.8, 203.0, 208.9; ICD10:C81-C86, C85.7, C90.0, C91-C95] Phase 2 [526641], [541857]
Therapeutic Class
Anticancer Agents
Company
Bayer Pharmaceuticals Corporation
Formula
C6382H9830N1672O1979S54
CAS Number
CAS 174722-31-7
SuperDrug ATC ID
V10XX02
Target and Pathway
Target(s) B-lymphocyte antigen CD20 Target Info [537294]
KEGG Pathway Hematopoietic cell lineage
References
Ref 526641Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopenia. Cancer Biother Radiopharm. 2003 Apr;18(2):165-78.
Ref 536361Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77. Epub 2007 Feb 20.
Ref 541857(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6777).
Ref 537294Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20. Mol Immunol. 2009 Jul;46(11-12):2419-23. Epub 2009 May 8.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.